Navigation Links
Carrington Settles Lawsuit, Sets Sights On Future
Date:2/1/2008

IRVING, Texas, Feb. 1 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) today announced the settlement of a lawsuit filed in February 2007 by Glamorpuss, Inc. The value of the settlement was not disclosed. Carrington maintains its position and denies any wrongdoing in the matter.

"We are eager to focus our full attention to analyzing our business and advancing DelSite's work with the bird flu vaccine, and needed to resolve some outstanding issues that occupied our time and resources at the corporate level," said Carlton E. Turner, PhD, Carrington's president and CEO. "We are glad to put this lawsuit behind us without significant financial impact."

DelSite Biotechnologies, Inc., is Carrington's wholly owned subsidiary that is developing its propriety GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs and vaccines. DelSite is currently developing a nasal powder vaccine using its GelVac(TM) formula with the H5N1 avian flu antigen and conducting studies which are funded in part by two grants from the NIAID (National Institute of Allergy and Infectious Diseases) of NIH (National Institutes of Health) under the Department of Health and Human Services.

"This is a very exciting time for us," Dr. Turner said. "Last month DelSite announced the successful completion and results of preclinical toxicology studies of the GelVac(TM) nasal powder influenza vaccine under FDA-reviewed protocols. This clears our path to proceed to a Phase I clinical trial in humans later this year. We are, in fact, awaiting arrival of the H5N1 antigen and are fully prepared to manufacture the vaccine for clinical testing upon its arrival. This vaccine system, if successful, could very well revolutionize how vaccines are formulated, stored, distributed and administered."

"GelVac(TM) has been shown to work with many antigens," Dr. Turner continued. "It is stable at room temperature, requires no needles, no preservatives, no cold storage and can be shipped anywhere free of the restrictive cold chain distribution systems required for traditional vaccines. As a nasal powder, it's patient-friendly and doesn't require administration by a medical professional. No painful injection could mean greater public acceptance and thus, public protection on a broader scale against specific diseases."

"At the corporate level, we are analyzing our business models and exploring strategies to move our business forward. We've incurred financial losses over recent years, due in part to Carrington's corporate funding of DelSite's initiatives and programs, and due in part to operational losses. We are now evaluating our business segments and growth opportunities with fresh perspectives. To that end, we just announced we have retained the services of an investment advisor to help us understand how we can capitalize on our considerable technologies and assets in a long-range business plan for the ultimate benefit of our shareholders and supporters. Improving shareholder value remains our highest priority."

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally- occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.

Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.

For Further Information, Contact:

Carlton E. Turner, PhD, President and CEO

Carrington Laboratories, Inc.

(972) 518-1300


'/>"/>
SOURCE Carrington Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
2. Carrington Reports Second Quarter 2007 Results
3. Carrington Completes $8 Million Financing
4. Carrington Reports on ISO 9001:2000 Inspection at Sabila Industrial in Costa Rica
5. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
6. Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market
7. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
8. Carrington Reports on ISO 9001:2000 Inspection
9. Carrington Reports Third Quarter 2007 Results
10. Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
11. Discover Testing Settles the Drinking Water Debate: Tap vs. Bottled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017  UBM and ... to announce their extended partnership and the third ... headlined by the 21 st Annual MassMEDIC ... taking place May 3-4, 2017. ... Technology Association (ADVAMED) President and CEO, Scott ...
(Date:3/22/2017)... 22, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... www.oramed.com ), a clinical-stage pharmaceutical company ... systems, announced today that Dr. Miriam Kidron ... presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing ... Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... New York , March 22, 2017 ... is largely fragmented, states a research report by Transparency ... S.A., Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted ... in 2015. The prominent players in this market are ... expand their product portfolio, which is likely to lead ...
(Date:3/22/2017)... /PRNewswire/ - FACIT announced a seed stage investment ... start-up created by FACIT focused on developing a ... with non-dilutive capital, achieves a targeted $3.0M financing ... Propellon to accelerate the nomination of a candidate ... entering a strategic partnership for clinical trials in ...
Breaking Biology Technology:
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis zum Jahr 2018 ... mehr als 50 Vertretern aus verschiedenen Branchen wurde aber klar, ... Prognose zu realisieren. ... Zu den Schwierigkeiten für Biobanking-Profis ... die Biobank, die Implementierung Zeit sparender Technologien, ein besseres ...
(Date:2/14/2017)... 2017  Wake Forest Baptist Medical Center today announced Julie ... executive officer (CEO). Freischlag joins the medical center on ... , M.D., who last year announced that he would ... after leading it since 2008.   As ... Forest Baptist,s academic health system, which includes Wake Forest ...
(Date:2/13/2017)... Feb. 13, 2017 Former 9/11 Commission border ... Committee, Janice Kephart of Identity Strategy Partners, ... Donald Trump,s "Executive Order: Protecting the Nation From ... 2017):  "As President Trump,s ,Travel Ban, Executive ... now essentially banned the travel ban, it is important ...
Breaking Biology News(10 mins):